Phase III safety study of Hib-MenCY-TT versus monovalent Hib vaccine in healthy infants

Phase 3, randomised, single-blind trial of Haemophilus influenzae type b and meningococcal vaccine in Haemophilus influenzae type b disease (Hib) and meningococcal disease (2 arms), sponsored by GSK. Primary endpoints: Occurrence of serious adverse events from dose 1 up to Day 30 after dose 3 and Occurrence of serious adverse events from dose 1 up to the day preceding the fourth dose.